Protocol Ledger

NCT06464991 · Phase III · RECRUITING

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Interventional Phase III clinical trial protocol NCT06464991 sponsored by Nanjing IASO Biotechnology Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-27 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06464991
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06464991
Protocol FieldVerified Registry Value
NCT IdentifierNCT06464991
Consolidated Lead SponsorNanjing IASO Biotechnology Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2024-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI